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Abstract
Background and purpose: The aim of the study was to inves-
tigate the relationship between syncope or presyncope occur-
rence and dysfunction of the cardiovascular autonomic sys-
tem in patients with Parkinson disease (PD).
Material and methods: Twenty-four PD patients were stud-
ied, including 10 subjects with syncope/presyncope and 
14 con trols without those symptoms. Ambulatory blood 
pressure monitoring (ABPM), Holter electrocardiographic
moni toring, carotid sinus massage, tilt test, and cardiac
scintigraphy with 123I metaiodobenzylguanidine (MIBG)
were performed.
Results: Differences between the two groups were found in
myocardial scintigraphy and ABPM. The stepwise regres-
sion analyses suggest that the values of late phase reduced
uptake of MIBG (95% CI: 0.0-0.77; p< 0.05) and day time
minimum systolic blood pressure (95% CI: 0.78-0.98; 
p= 0.007) may be related to the occurrence of syncope/pre-
syncope.
Conclusions: The findings suggest an association between
syncope/presyncope occurrence and dysfunction of the car-
diovascular autonomic system in PD patients. Both 123I
MIBG myocardial scintigraphy and ABPM may help iden-
tify a group of patients with an elevated risk for syncopic epi-
sodes which, in turn, may affect the choice of treatment. 
Key words: myocardial scintigraphy, Parkinson disease, syn-
cope.
St reszc zen ie
Wstêp i cel pracy: Celem pracy by³a analiza wp³ywu uszko-
dzenia unerwienia uk³adu sercowo-naczyniowego na wystêpo-
wanie omdleñ i stanów przedomdleniowych w grupie osób 
z chorob¹ Parkinsona (ChP).
Materia³ i metody: Do badania w³¹czono 24 chorych, u któ-
rych rozpoznano prawdopodobn¹ ChP. Grupê badan¹ 
stanowi³o 10 osób, które zg³asza³y wystêpowanie omdleñ 
i stanów przedomdleniowych, a grupê kontroln¹ 14 pacjen-
tów bez takich incydentów w wywiadzie. Protokó³ badawczy
obejmowa³ nastêpuj¹ce czynnoœci: masa¿ zatoki szyjnej, mo -
nitorowanie EKG i ciœnienia têtniczego metod¹ Holtera
(ABPM), test pochyleniowy oraz badanie scyntygraficzne ser-
ca z zastosowaniem 123I metajodobenzylguanidyny (MIBG).
Wyniki: W analizie regresji logistycznej wykazano istnienie
zwi¹zku miêdzy wystêpowaniem omdleñ/stanów przedomdle-
niowych a wynikami ABPM – minimalnym ciœnieniem skur-
czowym w interwale dziennym (95% CI: 0,78–0,98; 
p = 0,007), a tak¿e wynikami fazy póŸnej badania scynty-
graficznego serca z u¿yciem MIBG (95% CI: 0,0–0,77; 
p< 0,05). 
Wnioski: Wyniki badañ sugeruj¹ zwi¹zek pomiêdzy wystêpo-
waniem omdleñ i stanów przedomdleniowych a zaburzenia-
mi unerwienia autonomicznego uk³adu sercowo-naczynio-
wego u chorych na ChP. Scyntygrafia serca z u¿yciem 
123I MIBG oraz ABPM mog¹ byæ u¿yteczne przy ocenie
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nara¿enia na wystêpowanie omdleñ i stanów przedomdlenio-
wych w tej grupie pacjentów, co powinno mieæ wp³yw na
postêpowanie terapeutyczne. Scyntygrafia serca z u¿yciem
123I MIBG jest badaniem bezpiecznym. W przypadku metod
jakoœciowych, takich jak test pochyleniowy czy masa¿ zatoki
szyjnej, stwierdza siê wiêkszy odsetek powik³añ. 
S³owa kluczowe: scyntygrafia serca, choroba Parkinsona,
omdlenie. 
Introduction
Non-motor symptoms of Parkinson disease (PD),
according to Braak [1], are associated with neuropatho-
logical findings outside the substantia nigra. The cardio-
vascular autonomic nervous system is vulnerable to 
α-synuclein pathology. In early pathological Braak stages
(stages 1-2), a decreased density of TH-immunoreactive
nerve fibres in the epicardium was found. In later stages
(2-3) of PD, α-synuclein-immunoreactive neurites in 
the epicardium were found [2]. Metaiodobenzylguani-
dine (MIBG) labelling with 123iodine permits the visu-
alization of sympathetic innervation in vivo [3]; its uptake
correlates with adrenergic function. MIBG is a physio-
logical analogue of noradrenaline competing for active
uptake into the postganglionic sympathetic nerve termi-
nal [4]. The impaired cardiac uptake of 123I-MIBG in
PD patients is the result of involvement of postganglio -
nic sympathetic cardiac neurons and is observed in near-
ly all patients [5-8]. The most common index used for
imaging interpretation – the heart/mediastinum (H/M)
ratio – is reduced in PD patients from the earliest stages
of the disease and can be a sensitive tool for the detection
of silent autonomic dysfunction in patients without clini -
cal evidence of dysautonomia [9-11]. The sympathetic
denervation in PD occurs concurrently with parasympa-
thetic dysfunction and both can result in symptoms of
autonomic failure, such as orthostatic hypotension [12,13]
and falls [14]. The existence of correlations between the
severity of parkinsonian clinical features and MIBG
uptake remains controversial [4]. 123I-MIBG scintigra-
phy has been reported to be useful for differentiating PD
from other atypical parkinsonian syndromes, especially
MSA, when central and pre-ganglionic neurons are
involved [15]. The objective of the present study was to
investigate the correlation between cardiovascular auto-
nomic system dysfunction and cardiovascular symptoms,
i.e. the occurrence of syncope and presyncope in PD
patients. 
Material and methods
Patients with probable PD, diagnosed according to
Oertel and Quinn criteria [16], were assessed as poten-
tially eligible for the study. The study was approved by
the Ethics Committee of the Medical Centre for Post-
graduate Education in Warsaw, Poland.
Patients were excluded on the basis of the presence
of any disorder of the central or peripheral nervous sys-
tem other than PD, diabetes mellitus, heart disease
(ischaemic heart disease, cardiomyopathy), hyperten-
sion, or cancer. Patients receiving medications which
interfere with MIBG uptake or affect the autonomic
nervous system (e.g. beta-blockers) were also excluded.
Twenty-four patients with probable PD (10 females,
14 males; mean age, 62.3 years) were included in the
study and were divided into two groups. Group I con-
sisted of 10 patients with a history of syncope and/or
presyncope episodes (3 females, 7 males; mean age:
63.9). Group II comprised 14 patients with no such his-
tory (7 females, 7 males; mean age: 61.1). 
Syncope was defined as a transient, self-limited loss
of consciousness and pre-syncope as a condition in
which patients feel as if syncope was imminent. Symp-
toms associated with pre-syncope were similar to the
premonitory phase of true syncope: light-headedness,
nausea, sweating, weakness and visual disturbances or
non-specific symptoms, e.g. ‘dizziness’ [17].  
The average duration of PD was 8.6 years in 
group I and 7.3 years in group II (p = 0.534, t-test).
The average Hoehn and Yahr stage (in ‘on’ state) in
group I was 2.7 and in group II it was 2.57. The aver-
age daily levodopa-equivalent dose (mg) in group I was
570.0 and in group II it was 525.7. All patients from
group II were on monotherapy. Patients from group I
were also treated using other antiparkinsonian medica-
tions: amantadine (1 person), selegiline (3 persons), bi -
pe riden (1 person), pridinol (1 person) and entacapone 
(1 person).
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All study patients underwent physical and neurolo -
gical examinations. Historical features considering ques-
tions about circumstances just prior to the syncope, 
the onset and the end of the attack and the family back-
ground were taken. In group I, seven patients reported
features typical for syncope due to orthostatic hypoten-
sion – it appeared after standing up and after prolonged
standing in crowded, hot places. One patient associated
syncope with head rotation, while another three re port -
ed that it appeared after exertion. Patients did not have
vasovagal syncope in the history and cardiogenic causes
(conduction blocks, other dysrhythmias) were quite
unlikely as the primary causes of syncope. In group I only
one patient experienced syncope before PD was diag-
nosed. For the rest, the average time from PD onset to
the first syncope/presyncope experience was 5.8 years.
Echocardiogram, ambulatory blood pressure moni-
toring (ABPM), ambulatory electrocardiographic re -
cording (Holter ECG), carotid sinus massage, tilt test,
and myocardial scintigraphy with 123I-MIBG were per-
formed.
Echocardiogram (Philips Envisor C HD, MCMD
02 AA) was used to rule out heart diseases in which car-
diac syncope occurs [17].
ABPM (Mobilograph) was used to determine the
circadian rhythm of blood pressure (dipper or non-dip-
per profile), as well as daytime and nighttime values 
of minimum and maximum systolic blood pressure
(minSBP, maxSBP), diastolic blood pressure (minDBP,
maxDBP), and pulse pressure (PP).
Holter ECG recording (3-channel, Rozzin Holter
Recorder 151) was conducted to diagnose intermittent
arrhythmias. The rate-corrected QT (QTc), the stan-
dard deviation of NN intervals (SDNN), the average
heart rate (avrHR), the maximum heart rate (maxHR),
supraventricular ectopy (SVE), and ventricular ectopy
(VE) were analysed.
The carotid sinus reflex was tested during the carotid
sinus massage. The inclusion criterion for the massage
was the absence of atherosclerotic plaque in the carotid
artery (duplex Doppler ultrasonography). Massage was
performed in the supine position. ECG monitoring was
employed. After baseline measurements, the right carotid
artery was massaged for 5 seconds and, after a 2-minute-
break, the left one. The test was considered positive if,
during or immediately after the massage, an asystole
longer than 3 seconds or a fall in systolic blood pressure
of 50 mm Hg or more were present.
In the tilt test, the supine pre-tilt phase lasted 5 min-
u tes and the passive phase, at an angle of 70°, lasted 
45 minutes. Drug provocation was not used. The end
point of the test was the induction of syncope (test pos i-
tive) or completion of the planned duration of the tilt.
Myocardial scintigraphy with 123I-MIBG was per-
formed to detect alterations in myocardial sympathetic
activity [18]. Before intravenous administration of
approximately 111 MBq of 123I-MIBG, the thyroid 
was blocked by oral administration of 500 mg of potas-
sium perchlorate. Planar scintigraphic images of the
heart were acquired 20 minutes and 4 hours (early and
late phase) later. The H/M ratio was calculated for both
phases to quantify the cardiac MIBG uptake as a frac-
tion of the mean counts per pixel in the heart divided by
those in the upper mediastinum with a value of >1.8
considered normal on the basis of previous studies [18].
Group comparisons were performed using t-tests,
Fisher exact tests, and logistic regression analyses. The
strength of association between measures was evaluated
by Pearson correlations for normally distributed random
variables (avrHR, maxHR, QTc, SDNN) and by
Kendall tau-b rank correlation for non-normally dis-
tributed random variables (SVE, VE). 
Results
Group I showed significantly lower daytime values
of minSBP (p= 0.006), minDBP (p= 0.013), and PP
(p = 0.027) and lower nighttime values of minSBP 
(p = 0.023) and PP (p = 0.022) than group II 
(Table 1).
The Holter ECG monitoring chosen for analysis 
did not show any significant differences between the 
two study groups.
Carotid sinus massage was done in 6 patients from
group I and 10 from group II. The others were exclud-
ed, based on Doppler ultrasonography. Hypotension
during carotid massage was observed only in one patient
from group I.
The tilt test was performed with 8 patients from
group I and 13 from group II. Three patients refused to
continue the test immediately after the pre-tilt phase. Two
patients from group I and one patient from group II
exhibited syncope during the tilt phase. Orthostatic
hypotension was identified in all 3 patients with positive
test results.
The H/M ratio was reduced in all patients in group I
and II, both in early and late phases of myocardial
scintigraphy. The decrease in the H/M ratio was more
pronounced in group I, with the differences being sta-
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tistically significant in the late phase (p< 0.03; t-test)
(Fig. 1).
A low positive correlation was found between the
H/M ratio in the early phase of myocardial scintigra-
phy and avrHR (r= 0.48; p< 0.02). A weak negative
correlation was found between the H/M ratio in the late
phase of myocardial scintigraphy and VE (r= –0.36;
p< 0.02). Both the early phase (r= –0.49, p= 0.015)
and the late phase (r= –0.44, p= 0.031) H/M ratios
correlated negatively with nighttime minDBP values.
The stepwise regression analyses suggest that the
values of late phase reduced uptake of MIBG (95% CI:
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Method Patients with Patients without P-value
syncope/presyncope syncope/presyncope (t-test or *Fisher exact test)
n = 10 n = 14
ABPM – daytime
minSBP, mean [mm Hg] 83.0 95.7 0.006
maxSBP, mean [mm Hg] 149.0 162.8 0.07
minDBP, mean [mm Hg] 45.0 53.6 0.013
maxDBP, mean [mm Hg] 94.5 100.4 0.27
pulse pressure, mean [mm Hg] 40.73 48.6 0.027
ABPM – nighttime
minSBP, mean [mm Hg] 84.5 95.1 0.023
maxSBP, mean [mm Hg] 142.2 144.9 0.72
minDBP, mean [mm Hg] 50.4 53.4 0.44
maxDBP, mean [mm Hg] 91.9 88.6 0.46
pulse pressure, mean [mm Hg] 38.7 44.3 0.022
Holter EKG
QTc, mean [ms] 422.0 418.0 0.72
SDNN, mean [ms] 132.7 118.7 0.24
average heart rate, mean [1/s] 71.6 75.2 0.24
maximal heart rate, mean [1/s] 112.0 116.9 0.38
supraventricular ectopy, mean [n] 30.3 46.6 0.46
ventricular ectopy, mean [n] 41.6 8.7 0.23
Carotid sinus massage
normal 5 10 0.37*
abnormal 1 0
Tilt test
normal 6 12 0.24*
abnormal 2 1
Myocardial scintigraphy 
(heart/mediastinum ratio)
early phase, mean 1.37 1.49 0.06
late phase, mean 1.24 1.39 0.028
Table 1. Results and mean values for qualitative and quantitative methods for the assessment of the autonomic cardiovascular function in Parkinson’s disease patients 
with and without syncope/presyncope occurrence
ABPM – arterial blood pressure monitoring, ECG – electrocardiogram, SBP – systolic blood pressure, DBP – diastolic blood pressure, PP – pulse pressure, QTc – rate-corrected QT, 
SDNN – deviation of NN intervals
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Fig. 1. A) Patient with Parkinson disease and syncope/presyncope occurrence. Results of 123IMIBG cardiac scintigraphy: early phase (heart/mediastinum ratio = 1.33)
and late phase (heart/mediastinum ratio = 1.19). B) Patient with Parkinson disease without syncope and presyncope occurrence. Results of 123I-MIBG cardiac scin-
tigraphy: early phase (heart/mediastinum ratio = 1.63) and late phase (heart/mediastinum ratio = 1.50)
A B
0.0-0.77; p < 0.05) and daytime minSBP (95% CI:
0.78-0.98; p= 0.007) may be related to the occurrence
of syncope/presyncope.
Discussion
To the best of our knowledge, this is the first study
with PD patients in which it has been shown that 
the impaired cardiac uptake of 123I-MIBG specifying
the dysfunction of the sympathetic cardiac nervous 
system might be considered a risk factor for syn-
cope/presyncope occurrence. The resulting research
design, dividing patients into those with and without
syncope/presyncope on the basis of clinical interviews,
allowed for a fresh, assumption-free look at the possible
causes and correlates of syncopic incidents in PD.
Traditional, qualitative clinical methods are limited
in their ability to identify the cause of syncopic episodes
[17]. This was also shown in our study, where such
a cause was identified in only 3 of the 10 patients in
group I. Similarly, the fact that orthostatic hypotension
was identified during the non-pharmacological tilt test
in only 2 of the 10 patients in group I (8 patients exhibit-
ing no such symptoms) may suggest that any study
which limits the research group to PD patients with
orthostatic hypotension may possibly miss other causes
of syncopic episodes by looking at a research group pre-
selected with a limited screening device.
The present study shows statistically significant dif-
ferences in some ABPM measures and in the H/M
ratio of late phase myocardial scintigraphy between the
syncope and control group. Group I showed generally
lower values of daytime blood pressure and pulse pres-
sure, which may cause reduced cerebral blood flow and
the ensuing syncopic episodes. Regression analysis,
showing daytime minSBP as the best predictor of syn-
cope/presyncope, provides confirmation of this inter-
pretation. Lower H/M ratio values in group I suggest
a greater extent of cardiac sympathetic nervous system
impairment in these patients. Additionally, those ABPM
and H/M ratio values which differentiated group I from
group II did not correlate with each other. One excep-
tion was the nighttime minDBP. This pattern suggests
that the dysfunction of postganglionic sympathetic 
cardiac neurons and sympathetic control of blood ves-
sels occur independently. It also suggests that minSBP
may be the most important predictor, bearing in mind
the pathogenesis of syncope, especially neurally-medi-
ated as well as that associated with orthostatic hypoten-
sion. The decreasing arterial blood pressure could be
the effect of vasodilatation. In PD patients, syncope, like
orthostatic hypotension, seems to be the result of gene -
ralized sympathetic cardiovascular denervation [13].
This is also a group of older persons and other mecha-
nisms should be taken into consideration, for example
heart function (appropriate atrial contraction, heart rate).
In the present study heart dysfunction was an exclusion
criterion.
PD patients lose the nocturnal blood pressure dip
with a 24-hour blood pressure profile [19]. The nega-
tive correlation between nighttime minDBP and both
early and late phase H/M ratios may suggest an asso-
 cia tion between the level of dysfunction of the sympa-
thetic cardiac nervous system and non-dipper profile 
of ABPM. Taking into consideration the pathophysio -
logy, the impaired cardiac uptake of 123I-MIBG should
be perceived only as a determinant of the sympathetic
and parasympathetic denervation level of the cardio-
vascular system.
The low correlations found between the H/M ratio
in the early phase of myocardial scintigraphy and avrHR
as well as between the H/M ratio in the late phase of
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myocardial scintigraphy and VE may suggest an asso-
ciation between alterations in myocardial sympathetic
activity and changes in baseline cardiac rhythm [20,21].
However, their low strength only underscores the limi t-
ed utility of the qualitative assessments.
The present study suggests that a decreased H/M
ratio could correlate with syncope/presyncope occur-
rence. The demonstrated correlation between the H/M
ratio in the late phase of myocardial scintigraphy and
VE might suggest the existence of arrhythmias. How-
ever, a lack of correlation between VE and syncope/pre-
syncope precludes a suggestion that arrhythmias could
contribute to syncopic episodes. Decreased myocardial
MIBG uptake can predict major cardiac events. Its
prognostic value has been reported mainly in heart fail-
ure patients [22]. In the present study major cardiac
events were not noted, because heart disease was one of
the exclusion criteria.
The importance of medical history cannot be
replaced with modern technology in the case of syncope.
In group I seven patients reported features typical of
syncope due to orthostatic hypotension – it appeared
after standing up or after prolonged standing in crowd-
ed, hot places. One patient associated syncope with head
rotation, while another three reported that it appeared
after exertion. Only in two cases did patients reporting
features typical for syncope due to orthostatic hypoten-
sion exhibit syncope during the tilt phase of the tilt test.
The limitation of the study in this case is that, accord-
ing to the protocol, only a non-pharmacological test was
performed.
Both 123I MIBG myocardial scintigraphy and ABPM
may help identify a group of patients with an elevated
risk for syncopic episodes which, in turn, may affect the
choice of antiparkinsonian treatment: type of medication
and its dosage. MIBG cardiac scintigraphy is a very safe
method with no serious adverse effects [7,23]. Unifica-
tion of the technical standards (acquisition protocols and
positions of H/M ratio calculation regions of interest) is
necessary [4]. Traditional methods, particularly carotid
sinus massage, have a higher rate of complications. On
the other hand, they are less expensive, easier to arrange,
can lead to the proper diagnosis of syncope type, initia-
tion of its treatment and to the conclusion that there is
sympathetic dysfunction in a given patient. In the pre-
sent study positive results of sinus carotid massage and
tilt test were obtained in only a few patients. It allowed
for modification of their treatment and a start to educa-
tion regarding avoidance of triggering events, recogni-
tion of premonitory symptoms, etc.
The low number of studied patients limits the pow-
er of statistical inferences and suggests the need for
greater caution in generalizing the results. Further stud-
ies are needed to confirm our preliminary findings.
Conclusions
1. The findings suggest an association between syn-
cope/presyncope occurrence and dysfunction of the
cardiovascular autonomic system in PD patients.
2. Both 123I MIBG myocardial scintigraphy and ABPM
may help identify a group of patients with an elevat-
ed risk for syncopic episodes which, in turn, may
affect the choice of treatment.
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